American Diabetes Association
Browse
Online-Only_Supplemental_Material (1).pdf (333.99 kB)

Hypoglycemic response to dorzagliatin in a patient with GCK-MODY

Download (333.99 kB)
figure
posted on 2024-05-01, 20:23 authored by Yilin Zhao, Yumin Ma, Tianhao Ba, Xueyao Han, Qian Ren, Linong Ji

OBJECTIVE

Metformin, insulin, and insulin secretagogues do not alter HbA1c levels in glucokinase-maturity-onset diabetes of the young (GCK-MODY). However, the efficacy of the new hypoglycemic drugs on GCK-MODY remains unclear.

RESEARCH DESIGN AND METHODS

We describe a case of GCK-MODY with unchanged blood glucose under different therapies during an 8 years’ follow-up. His HbA1c and biochemical indices under different hypoglycemic treatments were recorded.

RESULTS

Oral antidiabetic drugs, including thiazolidinediones, dipeptidyl peptidase IV inhibitor, α-glucosidase inhibitor, and sodium-glucose cotransporter 2 inhibitor that had not been evaluated previously, did not improve the HbA1c level in this patient. However, the glucokinase activator dorzagliatin effectively and safely lowered his HbA1c level.

CONCLUSIONS

Dorzagliatin was effective and safe in this patient with GCK-MODY, providing potential application prospects for precise treatment of GCK-MODY with dorzagliatin.

Funding

This work was supported by the Beijing Municipal Commission of Science and Technology (grants Z201100005520012 and D131100005313008) and Peking University People’s Hospital Research and Development Fund (grant RDL2022-20).

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC